Author

S. C. Fussell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. Hwang· 2 shared N. Vinod· 2 shared A. E. D. Van Swearingen· 1 shared A. Kabanov· 1 shared A. V. Kabanov· 1 shared c. perou· 1 shared C. V. Pecot· 1 shared E. E. Livingston· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Hwang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC

N. Vinod, D. Hwang, S. C. Fussell, T. C. Owens, O. C. Tofade, S. Copling, J. D. Ramsey, P. D. Radler, H. M. Atkins, E. E. Livingston, J. A. Ezzel, M. Sokolsky, H. Yuan, c. perou, A. Kabanov

This study combines polymeric micelle-formulated TGFβ receptor inhibitors with Paclitaxel to show consistent anti-tumor effects across multiple TNBC mouse models.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma

N. Vinod, D. Hwang, S. H. Azam, A. E. D. Van Swearingen, E. Wayne, S. C. Fussell, M. Sokolsky-Papkov, C. V. Pecot, A. V. Kabanov

This study shows that a novel nanomicellar formulation of Resiquimod extends survival in a metastatic lung adenocarcinoma model more effectively than chemotherapy and anti-PD1 therapy.

bioRxiv · Dec 12, 2019Pharmacology & Toxicology